| 查看: 408 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
cainiaodui新虫 (小有名气)
|
[求助]
翻译求助
|
|
| Although Notch inhibitors are still preclinical, the monoclonal VEGF antibody bevacizumab is clinically available and represents a potential for combination therapy. As discussed above, some tumors are responsive to VEGF inhibition, although others are unresponsive and become resistant over time.This is most likely due to compensation by other angiogenic pathways that maintain the tumor vasculature. In patients with metastatic breast cancer, treatment with anti-VEGF therapy did not show a statistically significant increase in overall survival benefit.However, combination anti-angiogenic therapy may be useful in overcoming this resistance. |
回复此楼» 猜你喜欢
求调剂
已经有8人回复
-
353求调剂
已经有8人回复
-
材料工程302分求调剂
已经有3人回复
-
求
已经有3人回复
-
材料与化工363求推荐
已经有4人回复
-
085602调剂 初试总分335
已经有11人回复
-
081700学硕，323分，一志愿中国海洋大学求调剂学校
已经有12人回复
-
085410人工智能 初试316分 求调剂
已经有4人回复
-
285求调剂
已经有10人回复
-
材料化工306分找合适调剂
已经有11人回复
RXMCDM
版主 (文坛精英)
- 翻译EPI: 530
- 应助: 401 (硕士)
- 贵宾: 1.908
- 金币: 38947.6
- 散金: 4908
- 红花: 88
- 沙发: 4
- 帖子: 11453
- 在线: 1355.6小时
- 虫号: 2739168
- 注册: 2013-10-20
- 性别: GG
- 专业: 一般管理理论与研究方法论
- 管辖: 论文翻译
2楼2014-04-26 20:53:46
